JAK2 belongs to the Janus family of cytoplasmic tyrosine kinases (JAK1-JAK3, TYK2) and functions as a crucial mediator of signaling for hematopoietic cytokines and hormones such as erythropoietin (Epo), thrombopoietin (Tpo), interferon-γ (IFN-γ), several interleukins, growth hormone, prolactin, leptin and granulocytemacrophage colony-stimulating factor (GM-CSF) 1,2 . JAK2 serves as a triggering kinase for cytokine receptors, and phosphorylation and activation of downstream signaling proteins and the progression of signal transduction are dependent on its activity. JAK2 associates with the cytoplasmic domains of cytokine or hormone receptors, and ligand-induced receptor rearrangement facilitates JAK2 trans-phosphorylation of activation-loop Tyr1007 and Tyr1008 in JH1 (the tyrosine kinase domain), leading to its activation. Subsequent phosphorylation by JAK2 of tyrosine residues in the receptors creates docking sites for SH2-containing signaling proteins such as the signal transducer and activator of transcription (STAT) proteins 3, 4 .
JAK2 belongs to the Janus family of cytoplasmic tyrosine kinases (JAK1-JAK3, TYK2) and functions as a crucial mediator of signaling for hematopoietic cytokines and hormones such as erythropoietin (Epo), thrombopoietin (Tpo), interferon-γ (IFN-γ), several interleukins, growth hormone, prolactin, leptin and granulocytemacrophage colony-stimulating factor (GM-CSF) 1, 2 . JAK2 serves as a triggering kinase for cytokine receptors, and phosphorylation and activation of downstream signaling proteins and the progression of signal transduction are dependent on its activity. JAK2 associates with the cytoplasmic domains of cytokine or hormone receptors, and ligand-induced receptor rearrangement facilitates JAK2 trans-phosphorylation of activation-loop Tyr1007 and Tyr1008 in JH1 (the tyrosine kinase domain), leading to its activation. Subsequent phosphorylation by JAK2 of tyrosine residues in the receptors creates docking sites for SH2-containing signaling proteins such as the signal transducer and activator of transcription (STAT) proteins 3, 4 .
Phosphorylation is important in the regulation of JAK2, both positively and negatively. In the absence of cytokine stimulation, JAK2 is constitutively phosphorylated on Ser523 (ref. 5); however, upon activation, JAK2 becomes phosphorylated on as many as 20 tyrosine residues. In addition to Tyr1007 and Tyr1008, phosphorylation of Tyr637, Tyr813, Tyr868, Tyr966 and Tyr972 potentiate JAK2 activity, whereas phosphorylation of Ser523, Tyr119, Tyr221, Tyr317, Tyr570 and Tyr913 negatively regulate JAK2 (refs. 6-11) . Because JAK2 mediates crucial physiological functions such as cell proliferation, the kinase activity of JAK2 is tightly regulated through various means, including trans-acting proteins (tyrosine phosphatases, SOCS (suppressor of cytokine signaling) proteins) and JH2 (pseudokinase domain) [12] [13] [14] [15] .
Both biochemical and clinical evidence have demonstrated an important regulatory function for JH2 in JAKs. At present, 32 different mutations in JH2 of JAK2 have been shown to cause, or are linked to, hematological diseases 16 . The most frequent somatic mutation, V617F, results in constitutively active JAK2 and is responsible for >95% of cases of polycythemia vera and ~50% of cases of essential thrombocythemia and primary myelofibrosis [17] [18] [19] . The mechanism(s) by which JH2 negatively regulates the tyrosine kinase activity of JH1 is currently unknown, but it is likely to involve an intramolecular interaction between JH2 and JH1 (ref. 13) . In JAK2 and JAK3, deletion of JH2 increases basal JAK activity, and the JH2 domain has been shown to co-immunoprecipitate with the JH1 domain (in trans) 14, 20 . Currently, crystal structures are available for only JH1 of JAKs 21, 22 . JH2 is predicted to adopt a canonical protein kinase fold but to be catalytically inactive owing to amino acid substitutions of key catalytic residues that are conserved in active protein kinases-in particular, an aspartate residue in the catalytic loop (HRD motif). Therefore, JH2 in JAKs has been classified as a pseudokinase. Pseudokinases make up ~10% of the kinome and have been implicated in the regulation of various cellular functions, including tumorigenesis 23 .
The understanding of JAK kinase function, regulation and structure has been hampered by the difficulty of producing and purifying recombinant, soluble JAKs and their domains. This holds true also for JH2, and production and purification of JH2 has not been previously reported. We have now produced recombinant JAK2 JH2 Human JAK2 tyrosine kinase mediates signaling through numerous cytokine receptors. The JAK2 JH2 domain functions as a negative regulator and is presumed to be a catalytically inactive pseudokinase, but the mechanism(s) for its inhibition of JAK2 remains unknown. Mutations in JH2 lead to increased JAK2 activity, contributing to myeloproliferative neoplasms (MPNs). Here we show that JH2 is a dual-specificity protein kinase that phosphorylates two negative regulatory sites in JAK2: Ser523 and Tyr570. Inactivation of JH2 catalytic activity increased JAK2 basal activity and downstream signaling. Notably, different MPN mutations abrogated JH2 activity in cells, and in MPN (V617F) patient cells phosphorylation of Tyr570 was reduced, suggesting that loss of JH2 activity contributes to the pathogenesis of MPNs. These results identify the catalytic activity of JH2 as a previously unrecognized mechanism to control basal activity and signaling of JAK2.
A r t i c l e s domain using a baculovirus expression system, allowing us to address questions about the function of the JAK2 pseudokinase domain. We show that, contrary to the generally accepted belief, JH2 is an active protein kinase that phosphorylates two sites in JAK2-Ser523 and Tyr570-in a process that serves to maintain a low basal level of JAK2 activity. Moreover, JAK2 mutations that cause MPNs were found to abrogate JH2 activity. These results identify a previously unrecognized mechanism in the regulation of normal and pathogenic JAK2 and cytokine signaling.
RESULTS

Phosphorylation of purified JAK2 JH2 in vitro
We used insect cells (Sf9) to express JH2 as a glutathione S-transferase (GST) fusion protein ( Supplementary Figs. 1 and 2) . We used the purified GST-JH2 in an in vitro kinase assay, which showed a timedependent phosphorylation of JH2 with a strong preference for Mn 2+ as divalent cation (Fig. 1a,b) . A comparison of the autophosphorylation activity of purified JH1 versus JH2 of JAK2 indicated that JH2's activity is ~10% of that of JH1 (Fig. 1c) , which could explain why JH2 activity has previously gone unnoticed. To verify the autophosphorylation activity of JH2, we introduced a kinase-inactivating mutation, K581A, into JH2. This lysine (in β-strand 3 of the JH2 N-lobe) serves to coordinate the α-and β-phosphates of ATP in active protein kinases 24 . We produced and purified GST-JH2 (wild type) and the GST-K581A mutant side by side from insect cells. An in vitro kinase assay (Supplementary Fig. 3a) showed that the kinaseinactive JH2 mutant is devoid of autophosphorylation activity.
To further confirm that the observed kinase activity was due to JH2 autophosphorylation and not to phosphorylation by a contaminating protein kinase, we analyzed in vitro-translated JH2 (Supplementary Methods) using a kinase assay. Western blotting showed that in vitro-translated JH2 of JAK2 is autophosphorylated on tyrosine (Supplementary Fig. 3b) . Next, we carried out in vitro translation of wild-type JH2 and JH2 K581A, followed by His-tag purification, and subjected the proteins to an in vitro kinase assay in the presence of [γ-32 P]ATP. We detected autophosphorylation in the JH2 domain but not in the JH2 K581A mutant (Supplementary Fig. 3c ). Taken together, these results demonstrate that JH2 has autophosphorylation activity.
JAK2 JH2 is autophosphorylated on Ser523 and Tyr570
To study the kinase activity of the JAK2 pseudokinase domain in more detail, we expressed His-tagged JH2 in insect cells and purified it using Ni-NTA affinity and anion-exchange chromatography. JH2 eluted in two closely spaced peaks on an anion-exchange column ( Fig. 2a and Supplementary Fig. 4 ). During native PAGE, JH2 in peak 2 (JH2-peak2) migrated faster than JH2-peak1 (Fig. 2b) . The chromatography and electrophoresis data are suggestive of a higher phosphorylation state for JH2-peak2 than for JH2-peak1. We analyzed the autophosphorylation activities of the two JH2 samples in an in vitro kinase assay. Native PAGE showed the appearance of a faster-migrating band for both samples at later time points of the reaction, consistent with an increase in phosphorylation state (Fig. 2c) . We used LC-ESI-MS and LTQ-Orbitrap MS to identify the phosphorylated residues in JH2. JH2-peak1 was unphosphorylated at time zero and underwent autophosphorylation on Ser523 during the kinase reaction (data not shown). In contrast, JH2-peak2 was robustly (stoichiometrically) phosphorylated on Ser523 at time zero (thus explaining the migration difference between the proteins in the two peaks) and became phosphorylated additionally on Tyr570 during the kinase reaction (Fig. 2d) .
Further analysis of the JH2 autophosphorylation activity in kinase assays showed that JH2-peak2 has substantially higher tyrosine A r t i c l e s kinase activity than does JH2-peak1 (Fig. 3a) . To investigate the basis for this difference, we monitored the phosphorylation state of Ser523 by western blotting using an anti-pSer523 specific antibody 5 . Consistent with the MS results, Ser523 phosphorylation increased in JH2-peak1 during the kinase reaction, whereas JH2-peak2 was fully phosphorylated already at time zero, and the phosphorylation level of Ser523 remained constant during the reaction (Fig. 3a) . Moreover, the GST-JH2 K581A mutant purified from insect cells showed no phosphorylation on Ser523 ( Supplementary  Fig. 5 ), demonstrating that Ser523 is the de facto autophosphorylation site of JH2. These results, together with the results presented in Figure 2c , suggest that phosphorylation of Ser523 regulates the tyrosine kinase activity of JH2.
To address this possibility, we mutated Ser523 to alanine. Consistent with the hypothesis, S523A did not undergo tyrosine phosphorylation during an in vitro kinase assay (Fig. 3b) . Mutation of Tyr570 to phenylalanine did not affect Ser523 phosphorylation, but abolished tyrosine phosphorylation. These phosphospecific antibody data also confirm the MS identification of the two autophosphorylated residues in JH2: Ser523 and Tyr570. Notably, these two residues have previously been identified as negative regulatory sites in JAK2 (refs. 5,7,9,10) .
If the pseudokinase domain of JAK2 is an active protein kinase, using ATP as a phosphate donor, it should bind ATP with a physiological K d value. We evaluated the binding of ATP to JH2 of JAK2 using the fluorescent ATP analog 2′-(3′)-O-(N-methylanthraniloyl)-ATP (mant-ATP). The fluorescence emission scan showed a peak at ~440 nm only when MnCl 2 and JH2 were present along with mant-ATP (Fig. 3c) . Mant-ATP bound to JH2 with a K d of ~1 µM (Fig. 3d) , which is ~10% of the reported K d for JH1 of JAK2 (ref. 25) . Taken together, the in vitro data demonstrate that the pseudokinase domain of JAK2 is a dual-specificity serine and tyrosine kinase. Autophosphorylation of Ser523 is the primary event in JH2 activation, which enhances subsequent autophosphorylation of Tyr570. 
A r t i c l e s
Analysis of JAK2 JH2 in mammalian cells
To analyze the function of the catalytic activity of JH2 in a cellular context, we introduced the kinase-inactivating point mutation in JH2, K581A, into JAK2. We carried out expression of various JAK2 constructs in JAK2-deficient γ2A cells and analyzed JAK2 phosphorylation by western blotting. Wild-type JAK2 was tyrosine phosphorylated at a low level and, consistent with previous studies 5,7,9,10 , mutation of either Ser523 or Tyr570 increased JAK2 tyrosine phosphorylation of the JH1 activation loop (Tyr1007-Tyr1008), an indicator of JAK2 activation. Similar to the data for JAK2 S523A and JAK2 Y570F, JAK2 K581A showed a higher level of tyrosine phosphorylation than did wild-type JAK2 and, notably, Ser523 and Tyr570 sites were not phosphorylated in K581A (Fig. 4a) . In addition, these results corroborate the in vitro results (Fig. 3b) and show that, in cells, phosphorylation of Tyr570 is dependent on Ser523 phosphorylation of JH2.
To confirm the role of JH2 catalytic activity in phosphorylation of Ser523 and Tyr570, we expressed JH2 alone, wild-type JAK2 or the K581A mutant in γ2A cells. For wild-type JH2, both Ser523 and Tyr570 were phosphorylated, and the K581A mutation abolished their phosphorylation (Fig. 4b) . Moreover, in the context of fulllength JAK2 bearing a point mutation that abrogates JH1 activity (K882D), phosphorylation of Ser523 occurred to the same extent as in wild-type JAK2, and the K882D mutation did not markedly affect phosphorylation of Tyr570 (Fig. 4c) . Finally, in JAK2 constructs lacking the entire JH1 domain (JAK2del.JH1), phosphorylation of Ser523 and Tyr570 occurred to the same level as in wild-type JAK2 (Supplementary Fig. 6 ).
Last, we wanted to verify that the effects of the K581A mutation were due to abrogation of JH2 catalytic activity and minimize the possibility that they were caused by secondary conformational alterations in JH2. To this end, we introduced a more conservative mutation, K581R, and, separately, a distinct inactivating mutation, N678A (catalytic loop), into the full-length protein. The K581R mutant showed clear decreases in Ser523 and Tyr570 phosphorylation and an increase in JAK2 Tyr1007-Tyr1008 phosphorylation. We observed similar effects, albeit less pronounced, with the N678A mutant (Supplementary Fig. 7) . These in-cell data substantiate the conclusion that JH2 is a dual-specificity protein kinase that autophosphorylates Ser523 and Tyr570.
JH2 catalytic activity maintains low JAK2 basal activity
We investigated JH2 activity in cytokine receptor-mediated signaling by analyzing STAT activation in γ2A cells in response to cytokine stimulation. Compared to wild-type JAK2, the JAK2 mutants S523A, Y570F and K581A showed increased basal phosphorylation of STAT1, but the mutations did not influence the IFN-γ-induced STAT1 phosphorylation (Fig. 4d) . There was some variation in the level of STAT1 phosphorylation between the experiments (Fig. 4d  and Supplementary Fig. 8 ), but we consistently saw increased basal phosphorylation of STAT1, which was also observed with the K581A mutant in erythropoietin receptor (EpoR)-induced STAT5 phosphorylation (Fig. 4e) . We investigated the JH2 activity in the cytokineinduced transcriptional response by using reporter-gene analysis. Introduction of the K581A mutation into JAK2 increased the basal STAT1-and STAT5-dependent reporter-gene activation, but did not affect the IFN-γ or Epo-induced responses (Fig. 4f,g ). Taken together, these results indicate that JH2 catalytic activity is required to maintain a low basal level of JAK2 (JH1) activity.
JAK2 MPN-causing mutations affect JH2 catalytic activity
Our results showing that the catalytic activity of JH2 regulates the basal activity of JAK2 raises the question of the possible connection of this activity to human JAK2 mutants and disease pathogenesis. We were interested in understanding whether the catalytic activity of JH2 was involved in the pathogenesis of JAK2 MPN mutants. For this analysis, we chose three distinct MPN-causing JH2 mutants: V617F (exon 14, the predominant MPN-causing mutation), K539L (exon 12) 26 and R683S (exon 16) 27 .
Consistent with previous studies, the analyzed mutants showed high levels of tyrosine phosphorylation and activation of JAK2 in γ2A cells when compared to wild-type JAK2 (Fig. 5a) . Notably, all three mutants showed substantially decreased Ser523 phosphorylation. These results suggest that the JH2 mutations that cause MPN reduce or abrogate JH2 catalytic activity. To test this hypothesis directly, we analyzed JH2 alone and its V617F counterpart in γ2A cells. The results show that V617F, similar to K581A, abrogates Ser523 and Tyr570 phosphorylation (Fig. 5b) .
To determine whether altered JH2 function is also observed in clinical samples from MPN patients, and thus could be a causative mechanism for the disease, we isolated platelets from three MPN patients carrying the V617F mutation and from a healthy control and subjected them to Tpo stimulation (Supplementary Methods).
As a readout for JH2 activity, we analyzed the phosphorylation of JAK2 Tyr570. Tpo stimulation readily induced Tyr570 phosphorylation in control cells, but in patient samples Tyr570 phosphorylation was substantially reduced, and this reduction correlated with the V617F allelic burden of the patient cells (Supplementary Fig. 9 ). Taken together, these results show that MPN-causing mutations disturb the catalytic activity of JH2 and abrogate phosphorylation of negative regulatory residues that lead to increased basal activation of JAK2.
DISCUSSION
Protein kinases have been classified as pseudokinases if they lack conserved residues that are thought to be required for phosphoryl transfer, and if catalytic activity has not been detected 23, 28 . Recent studies have provided important new information and insights into the functions of this protein family. An example is provided by the structural characterization of VRK3, which is unable to bind ATP and obtains a pseudoactive conformation by filling the ATP-binding pocket by hydrophobic residues, thus retaining the pseudokinase status 29 . However, for several other proteins the functional status has been overturned, and proteins including CASK, haspin, WNK1, HER3(ErbB3) and STRADα have ATP-binding and (or) catalytic activity that can be achieved through noncanonical mechanisms [30] [31] [32] [33] [34] . Each of these pseudokinases uses a distinct mechanism to carry out its cellular functions. For example, WNK1 compensates for the missing ATP-binding lysine in β-strand 3 by instead using a lysine residue in the nucleotide-binding loop 32 . 
A r t i c l e s
The calcium-and calmodulin-activated serine-threonine kinase CASK displays atypical catalytic activity in that Mg 2+ inhibits its activity 30 . HER3 lacks the catalytic base aspartate, and the crystal structure revealed that it assumes an atypical conformation for active kinases, particularly in the αC helix and activation segment 33, 35 . However, HER3 was found to retain low-level kinase activity and phosphorylate its intracellular region in vitro, but the physiological role of this activity remains to be determined 33 . These results argue that each alleged pseudokinase needs to be functionally analyzed and scrutinized for possible catalytic activity. In this study, we have shown that, both in vitro and in cells, the pseudokinase domain of JAK2 is an active dual-specificity protein kinase that phosphorylates two previously identified negative regulatory sites in JAK2: Ser523 and Tyr570. Phosphorylation of these sites is required to maintain low basal activity of JAK2.
Our results on the catalytic activity of JH2 provide new insights into the regulation of JAK activation in signaling by various cytokines such as Epo, Tpo, IFN-γ, growth hormone, prolactin, interleukin-3 (IL-3), IL-5 and GM-CSF. In unstimulated cells, Ser523 is the only constitutively phosphorylated residue in JAK2 (ref. 5) , and phosphorylation of other sites, including Tyr570, occurs only upon cytokine stimulation and activation of JAK2 (refs. 9,10). The kinases responsible for phosphorylation of Ser523 and Tyr570 have not been identified, but the activity of JH1 was not required for these phosphorylation events 5, 7, 9, 10 . We show here that JH2 phosphorylates Ser523 and Tyr570, that autophosphorylation of Ser523 is the primary event in JH2 activation, and that it is observed in unstimulated conditions (Fig. 4d) . Cytokine-induced receptor dimerization and juxtaposition of the JAKs lead to other regulatory trans-phosphorylation events, including phosphorylation of Tyr570. Ser523 resides in the linker region between the SH2-like domain of JAK2 and JH2 ( Supplementary  Fig. 10) , and steric considerations indicate that it could be phosphorylated in cis. Tyr570, predicted to be in the β2-β3 loop of JH2, is distal to the JH2 active site and is presumed to be phosphorylated in trans by JH2 in another JAK2 molecule. A crystal structure of JH1-JH2 will be required to understand the mechanisms by which JH2 sterically inhibits JH1 and by which JH2-mediated phosphorylation of Ser523 and Tyr570 suppresses JH1 activity. Our results are consistent with a model whereby phosphorylation of Ser523 and Tyr570 strengthens the JH1-JH2 autoinhibitory interaction. The relatively low catalytic activity of JH2 is in accordance with autophosphorylation of regulatory residues as a physiological function for JH2, whereas JH1 is mainly responsible for phosphorylation of substrate proteins. The low catalytic activity, together with the crucial regulatory role of Ser523 and the atypical requirement for Mn 2+ for catalysis, has probably hampered the detection of JH2 activity.
The discovery of somatic mutations in JH2 of JAK2 in most Philadelphia chromosome-negative MPNs and other hematological malignancies have focused attention on the functional role of JH2 and implicated JAKs as important therapeutic targets. However, the underlying mechanisms for JAK2 hyperactivation in MPNs have remained obscure. Currently, several inhibitors targeting the JAK2 tyrosine kinase domain are in clinical trials for MPNs 36 . The JAK2 inhibitors show beneficial clinical effects and alleviate symptoms, but they do not substantially reduce the JAK2 mutant tumor load, and the inhibitors do not discriminate between normal and mutated JAK2. We show that MPN-causing JAK2 mutations disturb JH2 catalytic activity and remove the negative regulatory effects of Ser523 and Tyr570 phosphorylation in cell lines and in primary cells from MPN patients. These results identify a molecular pathogenic mechanism in MPNs and suggest that loss of JH2 function is involved in the hyperactive JAK2 MPN phenotype.
In conclusion, these studies have identified an unexpected regulatory mechanism for JH2 in JAK2. JH2 is an active protein kinase that autophosphorylates two negative regulatory residues, which is required to maintain low-level activity of JAK2 in the absence of cytokine stimulation. The discovery of JH2 catalytic activity and its connection to MPNs may also afford new approaches for the development of targeted therapies to combat JAK-mediated diseases.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/.
Note: Supplementary information is available on the Nature Structural & Molecular Biology website.
